On September 29, 2020 Immunomic Therapeutics, Inc. reported that it will participate in a panel at the MD Life Sciences Bio Innovation virtual conference in Maryland (Press release, Immunomic Therapeutics, SEP 29, 2020, View Source [SID1234567725]). On Monday, October 5, Chief Executive Officer at Immunomic, Dr. Bill Hearl, will participate in a panel titled, "Pandemic & Risk Mitigation: A Focus on Preparation & Resiliency" alongside Novavax’s President and CEO, Stanley Erck, and Emmes’ President, Anne Lindblad.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Bio Innovation Conference is presented by Maryland Life Sciences, a division of the Maryland Tech Council that is driving the future of life sciences in Maryland. This conference provides a forum for professionals from industry, academia and government to discuss trends and insight into Maryland’s burgeoning life sciences industry and topics related to funding, structuring, commercialization and government relations.

Panel details are as follows:

Title: Pandemic & Risk Mitigation: A Focus on Preparation & Resiliency

Panel Category: Life Science Track

Moderators:
Linda Segal, Principal, The McCormick Group
Gayatri Varma, Director, Transactions, Business Development & Licensing, AstraZeneca

Speakers:
Stanley Erck, President and CEO, Novavax
Bill Hearl, Ph.D., CEO, Immunomic Therapeutics
Anne Lindblad, Ph.D., President, Emmes

Panel Date and Time: Monday, October 5, 2020 10:25 AM

Location: MD Life Science Bio Innovation Virtual Event